Johnson & Johnson [JNJ] vs Merck & Co [MRK] Detailed Stock Comparison

Johnson & Johnson

NYSE
Loading...

Merck & Co., Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Johnson & Johnson wins in 10 metrics, Merck & Co., Inc. wins in 11 metrics, with 0 ties. Merck & Co., Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Johnson & Johnson Merck & Co., Inc. Better
P/E Ratio (TTM) 20.49 15.74 Merck & Co., Inc.
Price-to-Book Ratio 6.68 5.39 Merck & Co., Inc.
Debt-to-Equity Ratio 60.50 95.96 Johnson & Johnson
PEG Ratio 0.42 -0.82 Johnson & Johnson
EV/EBITDA 16.84 10.97 Merck & Co., Inc.
Profit Margin (TTM) 21.83% 28.08% Merck & Co., Inc.
Operating Margin (TTM) 26.72% 32.77% Merck & Co., Inc.
EBITDA Margin (TTM) 26.72% 32.77% Merck & Co., Inc.
Return on Equity 32.87% 36.88% Merck & Co., Inc.
Return on Assets (TTM) 13.46% 12.04% Johnson & Johnson
Free Cash Flow (TTM) $19.31B $12.36B Johnson & Johnson
Dividend Yield 2.09% 2.91% Merck & Co., Inc.
1-Year Return 53.32% 45.70% Johnson & Johnson
Price-to-Sales Ratio (TTM) 5.66 4.35 Merck & Co., Inc.
Enterprise Value $574.25B $319.41B Johnson & Johnson
EV/Revenue Ratio 5.96 4.91 Merck & Co., Inc.
Gross Profit Margin (TTM) 67.56% 66.15% Johnson & Johnson
Revenue per Share (TTM) $40 $26 Johnson & Johnson
Earnings per Share (Diluted) $11.04 $7.28 Johnson & Johnson
Beta (Stock Volatility) 0.33 0.28 Merck & Co., Inc.
Short % of Float 1.03% 1.12% Johnson & Johnson

Johnson & Johnson vs Merck & Co., Inc. Stock Performance Analysis

Loading Price Chart...

JNJ
MRK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Johnson & Johnson-2.16%1.51%3.95%-3.10%10.03%13.65%
Merck & Co., Inc.-3.49%-3.87%3.16%-0.46%14.60%7.94%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Johnson & Johnson53.32%46.67%48.70%108.58%263.36%290.52%
Merck & Co., Inc.45.70%8.90%55.40%123.23%252.74%262.85%

Performance & Financial Health Analysis: Johnson & Johnson vs Merck & Co., Inc.

MetricJNJMRK
Market Information
Market Cap i$555.84B$283.10B
Market Cap CategoryMega capMega cap
10 Day Avg. Volume i8,370,5669,732,998
90 Day Avg. Volume i7,752,9659,710,049
Last Close$235.66$114.90
52 Week Range$149.04 - $251.71$76.66 - $125.14
% from 52W High-6.38%-8.18%
All-Time High$251.71 (Mar 02, 2026)$134.63 (Jun 24, 2024)
% from All-Time High-6.38%-14.65%
Growth Metrics
Quarterly Revenue Growth0.10%0.05%
Quarterly Earnings Growth-0.52%-0.21%
Financial Health
Profit Margin (TTM) i0.22%0.28%
Operating Margin (TTM) i0.27%0.33%
Return on Equity (TTM) i0.33%0.37%
Debt to Equity (MRQ) i60.5095.96
Cash & Liquidity
Book Value per Share (MRQ)$33.87$21.26
Cash per Share (MRQ)$8.34$5.89
Operating Cash Flow (TTM) i$22.21B$16.47B
Levered Free Cash Flow (TTM) i$43.47B$11.89B
Dividends
Last 12-Month Dividend Yield i2.09%2.91%
Last 12-Month Dividend i$5.20$3.32

Valuation & Enterprise Metrics Analysis: Johnson & Johnson vs Merck & Co., Inc.

MetricJNJ (Apr 24, 2026)MRK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.4915.74
Forward P/E i17.8011.80
PEG Ratio i0.42-0.82
Price to Sales (TTM) i5.664.35
Price to Book (MRQ) i6.685.39
Market Capitalization
Market Capitalization i$555.84B$283.10B
Enterprise Value i$574.25B$319.41B
Enterprise Value Metrics
Enterprise to Revenue i5.964.91
Enterprise to EBITDA i16.8410.97
Risk & Other Metrics
Beta i0.330.28
Book Value per Share (MRQ) i$33.87$21.26

Financial Statements Comparison: Johnson & Johnson vs Merck & Co., Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricJNJ (2025)MRK (2025)
Revenue/Sales i94.19B65.01B
Cost of Goods Sold i30.26B16.38B
COGS % of Revenue i32.1%25.2%
Gross Profit i63.94B48.63B
Gross Margin i67.9%74.8%
Research & Development i14.67B15.79B
Operating Income (EBIT) i25.60B22.11B
Operating Margin i27.2%34.0%
EBITDA i35.16B29.11B
EBITDA Margin i37.3%44.8%
Pre-Tax Income i32.58B21.07B
Pre-Tax Income % of Revenue i34.6%32.4%
Income Tax i5.78B2.80B
Income Tax % of Revenue i6.1%4.3%
Net Income (Profit) i26.80B18.26B
Profit Margin i28.5%28.1%

Balance Sheet & Liquidity Metrics

MetricJNJ (2025)MRK (2025)
Cash & Equivalents i19.71B14.57B
Total Current Assets i55.62B43.52B
Total Current Assets % of Revenue i59.1%66.9%
Total Current Liabilities i54.13B28.33B
Total Current Liabilities % of Revenue i57.5%43.6%
Long-Term Debt i39.44B46.75B
Long-Term Debt % of Revenue i41.9%71.9%
Total Shareholders Equity i81.54B52.66B
Retained Earnings iN/A73.08B
Retained Earnings % of Revenue i0.0%112.4%
Property, Plant & Equipment i00

Cash Flow Statement Comparison

MetricJNJ (2025)MRK (2025)
Operating Cash Flow i22.21B18.49B
Operating Cash Flow % of Revenue i23.6%28.4%
Capital Expenditures i-4.83BN/A
Free Cash Flow i19.31B12.36B
FCF Margin i20.5%19.0%
Debt Repayment i-14.09B-2.50B
Common Stock Repurchase i-5.95B-5.08B

Short Interest & Institutional Ownership Analysis

MetricJNJMRK
Shares Short i22.27M27.72M
Short Ratio i2.902.69
Short % of Float i1.03%1.12%
Shares Outstanding i2.41B2.47B
Float Shares i2.41B2.47B
% Held by Insiders i0.06%0.06%
% Held by Institutions i75.84%81.44%
% Held by Public i24.10%18.50%

Dividend Analysis & Yield Comparison: Johnson & Johnson vs Merck & Co., Inc.

MetricJNJMRK
Last 12-Month Dividend i$5.20$3.32
Last 12-Month Dividend Yield i2.09%2.91%
3-Year Avg Annual Dividend i$4.97$3.16
3-Year Avg Dividend Yield i0.74%0.77%
3-Year Total Dividends i$14.92$9.48
Ex-Dividend DateFeb 24, 2026Mar 16, 2026